Frequency of Germline and Somatic <i<BRCA1</i< and <i<BRCA2</i< Mutations in Prostate Cancer: An Updated Systematic Review and Meta-Analysis

In prostate cancer (PC), the presence of <i<BRCA</i< somatic and/or germline mutation provides prognostic and predictive information. Meta-analysis aims to estimate the frequency of <i<BRCA</i< mutations in patients with PC (PCp). In November 2022, we reviewed literature sear...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Anna Amela Valsecchi [verfasserIn] Rossana Dionisio [verfasserIn] Olimpia Panepinto [verfasserIn] Jessica Paparo [verfasserIn] Andrea Palicelli [verfasserIn] Francesca Vignani [verfasserIn] Massimo Di Maio [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2023

Schlagwörter:	prostate cancer germline mutation somatic mutation meta-analysis

Übergeordnetes Werk:	In: Cancers - MDPI AG, 2010, 15(2023), 9, p 2435
Übergeordnetes Werk:	volume:15 ; year:2023 ; number:9, p 2435

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.3390/cancers15092435

Katalog-ID:	DOAJ090384687

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ090384687
003	DE-627
005	20240413035843.0
007	cr uuu---uuuuu
008	230526s2023 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.3390/cancers15092435 \|2 doi
035			\|a (DE-627)DOAJ090384687
035			\|a (DE-599)DOAJ97df34b35df74287a446ab34f8b4dbe0
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC254-282
100	0		\|a Anna Amela Valsecchi \|e verfasserin \|4 aut
245	1	0	\|a Frequency of Germline and Somatic <i<BRCA1</i< and <i<BRCA2</i< Mutations in Prostate Cancer: An Updated Systematic Review and Meta-Analysis
264		1	\|c 2023
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a In prostate cancer (PC), the presence of <i<BRCA</i< somatic and/or germline mutation provides prognostic and predictive information. Meta-analysis aims to estimate the frequency of <i<BRCA</i< mutations in patients with PC (PCp). In November 2022, we reviewed literature searching for all articles testing the proportion of <i<BRCA</i< mutations in PCp, without explicit enrichment for familiar risk. The frequency of germline and somatic <i<BRCA1</i< and/or <i<BRCA2</i< mutations was described in three stage disease populations (any/metastatic/metastatic castration-resistant PC, mCRPC). Out of 2253 identified articles, 40 were eligible. Here, 0.73% and 1.20% of any stage PCp, 0.94% and 1.10% of metastatic PCp, and 1.21% and 1.10% of mCRPC patients carried germline and somatic BRCA1 mutation, respectively; 3.25% and 6.29% of any stage PCp, 4.51% and 10.26% of metastatic PCp, and 3.90% and 10.52% of mCRPC patients carried germline and somatic BRCA2 mutation, respectively; and 4.47% and 7.18% of any stage PCp, 5.84% and 10.94% of metastatic PCp, and 5.26% and 11.26% of mCRPC patients carried germline and somatic <i<BRCA1/2</i< mutation, respectively. Somatic mutations are more common than germline and <i<BRCA2</i< are more common than <i<BRCA1</i< mutations; the frequency of mutations is higher in the metastatic setting. Despite that <i<BRCA</i< testing in PC is now standard in clinical practice, several open questions remain.
650		4	\|a prostate cancer
650		4	\|a <i<BRCA1</i<
650		4	\|a <i<BRCA2</i<
650		4	\|a germline mutation
650		4	\|a somatic mutation
650		4	\|a meta-analysis
653		0	\|a Neoplasms. Tumors. Oncology. Including cancer and carcinogens
700	0		\|a Rossana Dionisio \|e verfasserin \|4 aut
700	0		\|a Olimpia Panepinto \|e verfasserin \|4 aut
700	0		\|a Jessica Paparo \|e verfasserin \|4 aut
700	0		\|a Andrea Palicelli \|e verfasserin \|4 aut
700	0		\|a Francesca Vignani \|e verfasserin \|4 aut
700	0		\|a Massimo Di Maio \|e verfasserin \|4 aut
773	0	8	\|i In \|t Cancers \|d MDPI AG, 2010 \|g 15(2023), 9, p 2435 \|w (DE-627)614095670 \|w (DE-600)2527080-1 \|x 20726694 \|7 nnns
773	1	8	\|g volume:15 \|g year:2023 \|g number:9, p 2435
856	4	0	\|u https://doi.org/10.3390/cancers15092435 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/97df34b35df74287a446ab34f8b4dbe0 \|z kostenfrei
856	4	0	\|u https://www.mdpi.com/2072-6694/15/9/2435 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2072-6694 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 15 \|j 2023 \|e 9, p 2435

Indexfelder

author_variant	a a v aav r d rd o p op j p jp a p ap f v fv m d m mdm
matchkey_str	article:20726694:2023----::rqecogrlnadoaiirainiraiuainipottcneaudtd
hierarchy_sort_str	2023
callnumber-subject-code	RC
publishDate	2023
allfields	10.3390/cancers15092435 doi (DE-627)DOAJ090384687 (DE-599)DOAJ97df34b35df74287a446ab34f8b4dbe0 DE-627 ger DE-627 rakwb eng RC254-282 Anna Amela Valsecchi verfasserin aut Frequency of Germline and Somatic <i<BRCA1</i< and <i<BRCA2</i< Mutations in Prostate Cancer: An Updated Systematic Review and Meta-Analysis 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier In prostate cancer (PC), the presence of <i<BRCA</i< somatic and/or germline mutation provides prognostic and predictive information. Meta-analysis aims to estimate the frequency of <i<BRCA</i< mutations in patients with PC (PCp). In November 2022, we reviewed literature searching for all articles testing the proportion of <i<BRCA</i< mutations in PCp, without explicit enrichment for familiar risk. The frequency of germline and somatic <i<BRCA1</i< and/or <i<BRCA2</i< mutations was described in three stage disease populations (any/metastatic/metastatic castration-resistant PC, mCRPC). Out of 2253 identified articles, 40 were eligible. Here, 0.73% and 1.20% of any stage PCp, 0.94% and 1.10% of metastatic PCp, and 1.21% and 1.10% of mCRPC patients carried germline and somatic BRCA1 mutation, respectively; 3.25% and 6.29% of any stage PCp, 4.51% and 10.26% of metastatic PCp, and 3.90% and 10.52% of mCRPC patients carried germline and somatic BRCA2 mutation, respectively; and 4.47% and 7.18% of any stage PCp, 5.84% and 10.94% of metastatic PCp, and 5.26% and 11.26% of mCRPC patients carried germline and somatic <i<BRCA1/2</i< mutation, respectively. Somatic mutations are more common than germline and <i<BRCA2</i< are more common than <i<BRCA1</i< mutations; the frequency of mutations is higher in the metastatic setting. Despite that <i<BRCA</i< testing in PC is now standard in clinical practice, several open questions remain. prostate cancer <i<BRCA1</i< <i<BRCA2</i< germline mutation somatic mutation meta-analysis Neoplasms. Tumors. Oncology. Including cancer and carcinogens Rossana Dionisio verfasserin aut Olimpia Panepinto verfasserin aut Jessica Paparo verfasserin aut Andrea Palicelli verfasserin aut Francesca Vignani verfasserin aut Massimo Di Maio verfasserin aut In Cancers MDPI AG, 2010 15(2023), 9, p 2435 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:15 year:2023 number:9, p 2435 https://doi.org/10.3390/cancers15092435 kostenfrei https://doaj.org/article/97df34b35df74287a446ab34f8b4dbe0 kostenfrei https://www.mdpi.com/2072-6694/15/9/2435 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 15 2023 9, p 2435
spelling	10.3390/cancers15092435 doi (DE-627)DOAJ090384687 (DE-599)DOAJ97df34b35df74287a446ab34f8b4dbe0 DE-627 ger DE-627 rakwb eng RC254-282 Anna Amela Valsecchi verfasserin aut Frequency of Germline and Somatic <i<BRCA1</i< and <i<BRCA2</i< Mutations in Prostate Cancer: An Updated Systematic Review and Meta-Analysis 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier In prostate cancer (PC), the presence of <i<BRCA</i< somatic and/or germline mutation provides prognostic and predictive information. Meta-analysis aims to estimate the frequency of <i<BRCA</i< mutations in patients with PC (PCp). In November 2022, we reviewed literature searching for all articles testing the proportion of <i<BRCA</i< mutations in PCp, without explicit enrichment for familiar risk. The frequency of germline and somatic <i<BRCA1</i< and/or <i<BRCA2</i< mutations was described in three stage disease populations (any/metastatic/metastatic castration-resistant PC, mCRPC). Out of 2253 identified articles, 40 were eligible. Here, 0.73% and 1.20% of any stage PCp, 0.94% and 1.10% of metastatic PCp, and 1.21% and 1.10% of mCRPC patients carried germline and somatic BRCA1 mutation, respectively; 3.25% and 6.29% of any stage PCp, 4.51% and 10.26% of metastatic PCp, and 3.90% and 10.52% of mCRPC patients carried germline and somatic BRCA2 mutation, respectively; and 4.47% and 7.18% of any stage PCp, 5.84% and 10.94% of metastatic PCp, and 5.26% and 11.26% of mCRPC patients carried germline and somatic <i<BRCA1/2</i< mutation, respectively. Somatic mutations are more common than germline and <i<BRCA2</i< are more common than <i<BRCA1</i< mutations; the frequency of mutations is higher in the metastatic setting. Despite that <i<BRCA</i< testing in PC is now standard in clinical practice, several open questions remain. prostate cancer <i<BRCA1</i< <i<BRCA2</i< germline mutation somatic mutation meta-analysis Neoplasms. Tumors. Oncology. Including cancer and carcinogens Rossana Dionisio verfasserin aut Olimpia Panepinto verfasserin aut Jessica Paparo verfasserin aut Andrea Palicelli verfasserin aut Francesca Vignani verfasserin aut Massimo Di Maio verfasserin aut In Cancers MDPI AG, 2010 15(2023), 9, p 2435 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:15 year:2023 number:9, p 2435 https://doi.org/10.3390/cancers15092435 kostenfrei https://doaj.org/article/97df34b35df74287a446ab34f8b4dbe0 kostenfrei https://www.mdpi.com/2072-6694/15/9/2435 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 15 2023 9, p 2435
allfields_unstemmed	10.3390/cancers15092435 doi (DE-627)DOAJ090384687 (DE-599)DOAJ97df34b35df74287a446ab34f8b4dbe0 DE-627 ger DE-627 rakwb eng RC254-282 Anna Amela Valsecchi verfasserin aut Frequency of Germline and Somatic <i<BRCA1</i< and <i<BRCA2</i< Mutations in Prostate Cancer: An Updated Systematic Review and Meta-Analysis 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier In prostate cancer (PC), the presence of <i<BRCA</i< somatic and/or germline mutation provides prognostic and predictive information. Meta-analysis aims to estimate the frequency of <i<BRCA</i< mutations in patients with PC (PCp). In November 2022, we reviewed literature searching for all articles testing the proportion of <i<BRCA</i< mutations in PCp, without explicit enrichment for familiar risk. The frequency of germline and somatic <i<BRCA1</i< and/or <i<BRCA2</i< mutations was described in three stage disease populations (any/metastatic/metastatic castration-resistant PC, mCRPC). Out of 2253 identified articles, 40 were eligible. Here, 0.73% and 1.20% of any stage PCp, 0.94% and 1.10% of metastatic PCp, and 1.21% and 1.10% of mCRPC patients carried germline and somatic BRCA1 mutation, respectively; 3.25% and 6.29% of any stage PCp, 4.51% and 10.26% of metastatic PCp, and 3.90% and 10.52% of mCRPC patients carried germline and somatic BRCA2 mutation, respectively; and 4.47% and 7.18% of any stage PCp, 5.84% and 10.94% of metastatic PCp, and 5.26% and 11.26% of mCRPC patients carried germline and somatic <i<BRCA1/2</i< mutation, respectively. Somatic mutations are more common than germline and <i<BRCA2</i< are more common than <i<BRCA1</i< mutations; the frequency of mutations is higher in the metastatic setting. Despite that <i<BRCA</i< testing in PC is now standard in clinical practice, several open questions remain. prostate cancer <i<BRCA1</i< <i<BRCA2</i< germline mutation somatic mutation meta-analysis Neoplasms. Tumors. Oncology. Including cancer and carcinogens Rossana Dionisio verfasserin aut Olimpia Panepinto verfasserin aut Jessica Paparo verfasserin aut Andrea Palicelli verfasserin aut Francesca Vignani verfasserin aut Massimo Di Maio verfasserin aut In Cancers MDPI AG, 2010 15(2023), 9, p 2435 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:15 year:2023 number:9, p 2435 https://doi.org/10.3390/cancers15092435 kostenfrei https://doaj.org/article/97df34b35df74287a446ab34f8b4dbe0 kostenfrei https://www.mdpi.com/2072-6694/15/9/2435 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 15 2023 9, p 2435
allfieldsGer	10.3390/cancers15092435 doi (DE-627)DOAJ090384687 (DE-599)DOAJ97df34b35df74287a446ab34f8b4dbe0 DE-627 ger DE-627 rakwb eng RC254-282 Anna Amela Valsecchi verfasserin aut Frequency of Germline and Somatic <i<BRCA1</i< and <i<BRCA2</i< Mutations in Prostate Cancer: An Updated Systematic Review and Meta-Analysis 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier In prostate cancer (PC), the presence of <i<BRCA</i< somatic and/or germline mutation provides prognostic and predictive information. Meta-analysis aims to estimate the frequency of <i<BRCA</i< mutations in patients with PC (PCp). In November 2022, we reviewed literature searching for all articles testing the proportion of <i<BRCA</i< mutations in PCp, without explicit enrichment for familiar risk. The frequency of germline and somatic <i<BRCA1</i< and/or <i<BRCA2</i< mutations was described in three stage disease populations (any/metastatic/metastatic castration-resistant PC, mCRPC). Out of 2253 identified articles, 40 were eligible. Here, 0.73% and 1.20% of any stage PCp, 0.94% and 1.10% of metastatic PCp, and 1.21% and 1.10% of mCRPC patients carried germline and somatic BRCA1 mutation, respectively; 3.25% and 6.29% of any stage PCp, 4.51% and 10.26% of metastatic PCp, and 3.90% and 10.52% of mCRPC patients carried germline and somatic BRCA2 mutation, respectively; and 4.47% and 7.18% of any stage PCp, 5.84% and 10.94% of metastatic PCp, and 5.26% and 11.26% of mCRPC patients carried germline and somatic <i<BRCA1/2</i< mutation, respectively. Somatic mutations are more common than germline and <i<BRCA2</i< are more common than <i<BRCA1</i< mutations; the frequency of mutations is higher in the metastatic setting. Despite that <i<BRCA</i< testing in PC is now standard in clinical practice, several open questions remain. prostate cancer <i<BRCA1</i< <i<BRCA2</i< germline mutation somatic mutation meta-analysis Neoplasms. Tumors. Oncology. Including cancer and carcinogens Rossana Dionisio verfasserin aut Olimpia Panepinto verfasserin aut Jessica Paparo verfasserin aut Andrea Palicelli verfasserin aut Francesca Vignani verfasserin aut Massimo Di Maio verfasserin aut In Cancers MDPI AG, 2010 15(2023), 9, p 2435 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:15 year:2023 number:9, p 2435 https://doi.org/10.3390/cancers15092435 kostenfrei https://doaj.org/article/97df34b35df74287a446ab34f8b4dbe0 kostenfrei https://www.mdpi.com/2072-6694/15/9/2435 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 15 2023 9, p 2435
allfieldsSound	10.3390/cancers15092435 doi (DE-627)DOAJ090384687 (DE-599)DOAJ97df34b35df74287a446ab34f8b4dbe0 DE-627 ger DE-627 rakwb eng RC254-282 Anna Amela Valsecchi verfasserin aut Frequency of Germline and Somatic <i<BRCA1</i< and <i<BRCA2</i< Mutations in Prostate Cancer: An Updated Systematic Review and Meta-Analysis 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier In prostate cancer (PC), the presence of <i<BRCA</i< somatic and/or germline mutation provides prognostic and predictive information. Meta-analysis aims to estimate the frequency of <i<BRCA</i< mutations in patients with PC (PCp). In November 2022, we reviewed literature searching for all articles testing the proportion of <i<BRCA</i< mutations in PCp, without explicit enrichment for familiar risk. The frequency of germline and somatic <i<BRCA1</i< and/or <i<BRCA2</i< mutations was described in three stage disease populations (any/metastatic/metastatic castration-resistant PC, mCRPC). Out of 2253 identified articles, 40 were eligible. Here, 0.73% and 1.20% of any stage PCp, 0.94% and 1.10% of metastatic PCp, and 1.21% and 1.10% of mCRPC patients carried germline and somatic BRCA1 mutation, respectively; 3.25% and 6.29% of any stage PCp, 4.51% and 10.26% of metastatic PCp, and 3.90% and 10.52% of mCRPC patients carried germline and somatic BRCA2 mutation, respectively; and 4.47% and 7.18% of any stage PCp, 5.84% and 10.94% of metastatic PCp, and 5.26% and 11.26% of mCRPC patients carried germline and somatic <i<BRCA1/2</i< mutation, respectively. Somatic mutations are more common than germline and <i<BRCA2</i< are more common than <i<BRCA1</i< mutations; the frequency of mutations is higher in the metastatic setting. Despite that <i<BRCA</i< testing in PC is now standard in clinical practice, several open questions remain. prostate cancer <i<BRCA1</i< <i<BRCA2</i< germline mutation somatic mutation meta-analysis Neoplasms. Tumors. Oncology. Including cancer and carcinogens Rossana Dionisio verfasserin aut Olimpia Panepinto verfasserin aut Jessica Paparo verfasserin aut Andrea Palicelli verfasserin aut Francesca Vignani verfasserin aut Massimo Di Maio verfasserin aut In Cancers MDPI AG, 2010 15(2023), 9, p 2435 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:15 year:2023 number:9, p 2435 https://doi.org/10.3390/cancers15092435 kostenfrei https://doaj.org/article/97df34b35df74287a446ab34f8b4dbe0 kostenfrei https://www.mdpi.com/2072-6694/15/9/2435 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 15 2023 9, p 2435
language	English
source	In Cancers 15(2023), 9, p 2435 volume:15 year:2023 number:9, p 2435
sourceStr	In Cancers 15(2023), 9, p 2435 volume:15 year:2023 number:9, p 2435
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	prostate cancer <i<BRCA1</i< <i<BRCA2</i< germline mutation somatic mutation meta-analysis Neoplasms. Tumors. Oncology. Including cancer and carcinogens
isfreeaccess_bool	true
container_title	Cancers
authorswithroles_txt_mv	Anna Amela Valsecchi @@aut@@ Rossana Dionisio @@aut@@ Olimpia Panepinto @@aut@@ Jessica Paparo @@aut@@ Andrea Palicelli @@aut@@ Francesca Vignani @@aut@@ Massimo Di Maio @@aut@@
publishDateDaySort_date	2023-01-01T00:00:00Z
hierarchy_top_id	614095670
id	DOAJ090384687
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ090384687</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413035843.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230526s2023 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/cancers15092435</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ090384687</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ97df34b35df74287a446ab34f8b4dbe0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Anna Amela Valsecchi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Frequency of Germline and Somatic <i<BRCA1</i< and <i<BRCA2</i< Mutations in Prostate Cancer: An Updated Systematic Review and Meta-Analysis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In prostate cancer (PC), the presence of <i<BRCA</i< somatic and/or germline mutation provides prognostic and predictive information. Meta-analysis aims to estimate the frequency of <i<BRCA</i< mutations in patients with PC (PCp). In November 2022, we reviewed literature searching for all articles testing the proportion of <i<BRCA</i< mutations in PCp, without explicit enrichment for familiar risk. The frequency of germline and somatic <i<BRCA1</i< and/or <i<BRCA2</i< mutations was described in three stage disease populations (any/metastatic/metastatic castration-resistant PC, mCRPC). Out of 2253 identified articles, 40 were eligible. Here, 0.73% and 1.20% of any stage PCp, 0.94% and 1.10% of metastatic PCp, and 1.21% and 1.10% of mCRPC patients carried germline and somatic BRCA1 mutation, respectively; 3.25% and 6.29% of any stage PCp, 4.51% and 10.26% of metastatic PCp, and 3.90% and 10.52% of mCRPC patients carried germline and somatic BRCA2 mutation, respectively; and 4.47% and 7.18% of any stage PCp, 5.84% and 10.94% of metastatic PCp, and 5.26% and 11.26% of mCRPC patients carried germline and somatic <i<BRCA1/2</i< mutation, respectively. Somatic mutations are more common than germline and <i<BRCA2</i< are more common than <i<BRCA1</i< mutations; the frequency of mutations is higher in the metastatic setting. Despite that <i<BRCA</i< testing in PC is now standard in clinical practice, several open questions remain.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">prostate cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a"><i<BRCA1</i<</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a"><i<BRCA2</i<</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">germline mutation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">somatic mutation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">meta-analysis</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rossana Dionisio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Olimpia Panepinto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jessica Paparo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Andrea Palicelli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Francesca Vignani</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Massimo Di Maio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Cancers</subfield><subfield code="d">MDPI AG, 2010</subfield><subfield code="g">15(2023), 9, p 2435</subfield><subfield code="w">(DE-627)614095670</subfield><subfield code="w">(DE-600)2527080-1</subfield><subfield code="x">20726694</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:15</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:9, p 2435</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/cancers15092435</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/97df34b35df74287a446ab34f8b4dbe0</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2072-6694/15/9/2435</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2072-6694</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">15</subfield><subfield code="j">2023</subfield><subfield code="e">9, p 2435</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Anna Amela Valsecchi
spellingShingle	Anna Amela Valsecchi misc RC254-282 misc prostate cancer misc <i<BRCA1</i< misc <i<BRCA2</i< misc germline mutation misc somatic mutation misc meta-analysis misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens Frequency of Germline and Somatic <i<BRCA1</i< and <i<BRCA2</i< Mutations in Prostate Cancer: An Updated Systematic Review and Meta-Analysis
authorStr	Anna Amela Valsecchi
ppnlink_with_tag_str_mv	@@773@@(DE-627)614095670
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC254-282
illustrated	Not Illustrated
issn	20726694
topic_title	RC254-282 Frequency of Germline and Somatic <i<BRCA1</i< and <i<BRCA2</i< Mutations in Prostate Cancer: An Updated Systematic Review and Meta-Analysis prostate cancer <i<BRCA1</i< <i<BRCA2</i< germline mutation somatic mutation meta-analysis
topic	misc RC254-282 misc prostate cancer misc <i<BRCA1</i< misc <i<BRCA2</i< misc germline mutation misc somatic mutation misc meta-analysis misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_unstemmed	misc RC254-282 misc prostate cancer misc <i<BRCA1</i< misc <i<BRCA2</i< misc germline mutation misc somatic mutation misc meta-analysis misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_browse	misc RC254-282 misc prostate cancer misc <i<BRCA1</i< misc <i<BRCA2</i< misc germline mutation misc somatic mutation misc meta-analysis misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Cancers
hierarchy_parent_id	614095670
hierarchy_top_title	Cancers
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)614095670 (DE-600)2527080-1
title	Frequency of Germline and Somatic <i<BRCA1</i< and <i<BRCA2</i< Mutations in Prostate Cancer: An Updated Systematic Review and Meta-Analysis
ctrlnum	(DE-627)DOAJ090384687 (DE-599)DOAJ97df34b35df74287a446ab34f8b4dbe0
title_full	Frequency of Germline and Somatic <i<BRCA1</i< and <i<BRCA2</i< Mutations in Prostate Cancer: An Updated Systematic Review and Meta-Analysis
author_sort	Anna Amela Valsecchi
journal	Cancers
journalStr	Cancers
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2023
contenttype_str_mv	txt
author_browse	Anna Amela Valsecchi Rossana Dionisio Olimpia Panepinto Jessica Paparo Andrea Palicelli Francesca Vignani Massimo Di Maio
container_volume	15
class	RC254-282
format_se	Elektronische Aufsätze
author-letter	Anna Amela Valsecchi
doi_str_mv	10.3390/cancers15092435
author2-role	verfasserin
title_sort	frequency of germline and somatic <i<brca1</i< and <i<brca2</i< mutations in prostate cancer: an updated systematic review and meta-analysis
callnumber	RC254-282
title_auth	Frequency of Germline and Somatic <i<BRCA1</i< and <i<BRCA2</i< Mutations in Prostate Cancer: An Updated Systematic Review and Meta-Analysis
abstract	In prostate cancer (PC), the presence of <i<BRCA</i< somatic and/or germline mutation provides prognostic and predictive information. Meta-analysis aims to estimate the frequency of <i<BRCA</i< mutations in patients with PC (PCp). In November 2022, we reviewed literature searching for all articles testing the proportion of <i<BRCA</i< mutations in PCp, without explicit enrichment for familiar risk. The frequency of germline and somatic <i<BRCA1</i< and/or <i<BRCA2</i< mutations was described in three stage disease populations (any/metastatic/metastatic castration-resistant PC, mCRPC). Out of 2253 identified articles, 40 were eligible. Here, 0.73% and 1.20% of any stage PCp, 0.94% and 1.10% of metastatic PCp, and 1.21% and 1.10% of mCRPC patients carried germline and somatic BRCA1 mutation, respectively; 3.25% and 6.29% of any stage PCp, 4.51% and 10.26% of metastatic PCp, and 3.90% and 10.52% of mCRPC patients carried germline and somatic BRCA2 mutation, respectively; and 4.47% and 7.18% of any stage PCp, 5.84% and 10.94% of metastatic PCp, and 5.26% and 11.26% of mCRPC patients carried germline and somatic <i<BRCA1/2</i< mutation, respectively. Somatic mutations are more common than germline and <i<BRCA2</i< are more common than <i<BRCA1</i< mutations; the frequency of mutations is higher in the metastatic setting. Despite that <i<BRCA</i< testing in PC is now standard in clinical practice, several open questions remain.
abstractGer	In prostate cancer (PC), the presence of <i<BRCA</i< somatic and/or germline mutation provides prognostic and predictive information. Meta-analysis aims to estimate the frequency of <i<BRCA</i< mutations in patients with PC (PCp). In November 2022, we reviewed literature searching for all articles testing the proportion of <i<BRCA</i< mutations in PCp, without explicit enrichment for familiar risk. The frequency of germline and somatic <i<BRCA1</i< and/or <i<BRCA2</i< mutations was described in three stage disease populations (any/metastatic/metastatic castration-resistant PC, mCRPC). Out of 2253 identified articles, 40 were eligible. Here, 0.73% and 1.20% of any stage PCp, 0.94% and 1.10% of metastatic PCp, and 1.21% and 1.10% of mCRPC patients carried germline and somatic BRCA1 mutation, respectively; 3.25% and 6.29% of any stage PCp, 4.51% and 10.26% of metastatic PCp, and 3.90% and 10.52% of mCRPC patients carried germline and somatic BRCA2 mutation, respectively; and 4.47% and 7.18% of any stage PCp, 5.84% and 10.94% of metastatic PCp, and 5.26% and 11.26% of mCRPC patients carried germline and somatic <i<BRCA1/2</i< mutation, respectively. Somatic mutations are more common than germline and <i<BRCA2</i< are more common than <i<BRCA1</i< mutations; the frequency of mutations is higher in the metastatic setting. Despite that <i<BRCA</i< testing in PC is now standard in clinical practice, several open questions remain.
abstract_unstemmed	In prostate cancer (PC), the presence of <i<BRCA</i< somatic and/or germline mutation provides prognostic and predictive information. Meta-analysis aims to estimate the frequency of <i<BRCA</i< mutations in patients with PC (PCp). In November 2022, we reviewed literature searching for all articles testing the proportion of <i<BRCA</i< mutations in PCp, without explicit enrichment for familiar risk. The frequency of germline and somatic <i<BRCA1</i< and/or <i<BRCA2</i< mutations was described in three stage disease populations (any/metastatic/metastatic castration-resistant PC, mCRPC). Out of 2253 identified articles, 40 were eligible. Here, 0.73% and 1.20% of any stage PCp, 0.94% and 1.10% of metastatic PCp, and 1.21% and 1.10% of mCRPC patients carried germline and somatic BRCA1 mutation, respectively; 3.25% and 6.29% of any stage PCp, 4.51% and 10.26% of metastatic PCp, and 3.90% and 10.52% of mCRPC patients carried germline and somatic BRCA2 mutation, respectively; and 4.47% and 7.18% of any stage PCp, 5.84% and 10.94% of metastatic PCp, and 5.26% and 11.26% of mCRPC patients carried germline and somatic <i<BRCA1/2</i< mutation, respectively. Somatic mutations are more common than germline and <i<BRCA2</i< are more common than <i<BRCA1</i< mutations; the frequency of mutations is higher in the metastatic setting. Despite that <i<BRCA</i< testing in PC is now standard in clinical practice, several open questions remain.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	9, p 2435
title_short	Frequency of Germline and Somatic <i<BRCA1</i< and <i<BRCA2</i< Mutations in Prostate Cancer: An Updated Systematic Review and Meta-Analysis
url	https://doi.org/10.3390/cancers15092435 https://doaj.org/article/97df34b35df74287a446ab34f8b4dbe0 https://www.mdpi.com/2072-6694/15/9/2435 https://doaj.org/toc/2072-6694
remote_bool	true
author2	Rossana Dionisio Olimpia Panepinto Jessica Paparo Andrea Palicelli Francesca Vignani Massimo Di Maio
author2Str	Rossana Dionisio Olimpia Panepinto Jessica Paparo Andrea Palicelli Francesca Vignani Massimo Di Maio
ppnlink	614095670
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.3390/cancers15092435
callnumber-a	RC254-282
up_date	2024-07-03T14:27:43.898Z
_version_	1803568403082903553
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ090384687</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413035843.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230526s2023 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/cancers15092435</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ090384687</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ97df34b35df74287a446ab34f8b4dbe0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Anna Amela Valsecchi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Frequency of Germline and Somatic <i<BRCA1</i< and <i<BRCA2</i< Mutations in Prostate Cancer: An Updated Systematic Review and Meta-Analysis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In prostate cancer (PC), the presence of <i<BRCA</i< somatic and/or germline mutation provides prognostic and predictive information. Meta-analysis aims to estimate the frequency of <i<BRCA</i< mutations in patients with PC (PCp). In November 2022, we reviewed literature searching for all articles testing the proportion of <i<BRCA</i< mutations in PCp, without explicit enrichment for familiar risk. The frequency of germline and somatic <i<BRCA1</i< and/or <i<BRCA2</i< mutations was described in three stage disease populations (any/metastatic/metastatic castration-resistant PC, mCRPC). Out of 2253 identified articles, 40 were eligible. Here, 0.73% and 1.20% of any stage PCp, 0.94% and 1.10% of metastatic PCp, and 1.21% and 1.10% of mCRPC patients carried germline and somatic BRCA1 mutation, respectively; 3.25% and 6.29% of any stage PCp, 4.51% and 10.26% of metastatic PCp, and 3.90% and 10.52% of mCRPC patients carried germline and somatic BRCA2 mutation, respectively; and 4.47% and 7.18% of any stage PCp, 5.84% and 10.94% of metastatic PCp, and 5.26% and 11.26% of mCRPC patients carried germline and somatic <i<BRCA1/2</i< mutation, respectively. Somatic mutations are more common than germline and <i<BRCA2</i< are more common than <i<BRCA1</i< mutations; the frequency of mutations is higher in the metastatic setting. Despite that <i<BRCA</i< testing in PC is now standard in clinical practice, several open questions remain.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">prostate cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a"><i<BRCA1</i<</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a"><i<BRCA2</i<</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">germline mutation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">somatic mutation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">meta-analysis</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rossana Dionisio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Olimpia Panepinto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jessica Paparo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Andrea Palicelli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Francesca Vignani</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Massimo Di Maio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Cancers</subfield><subfield code="d">MDPI AG, 2010</subfield><subfield code="g">15(2023), 9, p 2435</subfield><subfield code="w">(DE-627)614095670</subfield><subfield code="w">(DE-600)2527080-1</subfield><subfield code="x">20726694</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:15</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:9, p 2435</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/cancers15092435</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/97df34b35df74287a446ab34f8b4dbe0</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2072-6694/15/9/2435</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2072-6694</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">15</subfield><subfield code="j">2023</subfield><subfield code="e">9, p 2435</subfield></datafield></record></collection>
score	7.40176

Nicht das Richtige dabei?

Schreiben Sie uns!

Frequency of Germline and Somatic <i<BRCA1</i< and <i<BRCA2</i< Mutations in Prostate Cancer: An Updated Systematic Review and Meta-Analysis

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?